Covered recipient · General Payments record
AAMIR Z JAMAL
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$1,061.81
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $997.27 | 49 |
| Education | $64.54 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $234.75 | 6 |
| AKEBIA THERAPEUTICS INC | $161.44 | 9 |
| Amgen Inc. | $145.56 | 15 |
| Novo Nordisk Inc | $125.71 | 5 |
| KYOWA KIRIN, INC. | $99.04 | 4 |
| OPKO Pharmaceuticals, LLC | $59.20 | 3 |
| Travere Therapeutics, Inc. | $53.46 | 2 |
| Calliditas Therapeutics US Inc. | $35.43 | 1 |
| AstraZeneca Pharmaceuticals LP | $32.69 | 1 |
| CorMedix Inc. | $30.22 | 1 |
| Otsuka America Pharmaceutical, Inc. | $27.27 | 1 |
| Ardelyx, Inc. | $19.82 | 1 |
| Fresenius USA Marketing, Inc. | $19.79 | 1 |
| Mallinckrodt Hospital Products Inc. | $17.43 | 1 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AAMIR Z JAMAL
NPI 1558377523 · CMS profile ID 251829
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
SAN DIMAS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $1,061.81 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $32.69 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206588213 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $24.90 | 1 |
| PY2025 | Principal investigator | $1,471,601.02 | 167 |
| PY2024 | Recipient | $29,425.21 | 2 |
| PY2024 | Principal investigator | $1,181,501.87 | 263 |
| PY2023 | Recipient | $217.78 | 3 |
| PY2023 | Principal investigator | $322,549.59 | 383 |
| PY2022 | Recipient | $31,851.60 | 3 |
| PY2022 | Principal investigator | $307,450.33 | 500 |
| PY2021 | Principal investigator | $679,075.50 | 672 |
| PY2020 | Recipient | $4,193.87 | 2 |
| PY2020 | Principal investigator | $813,384.42 | 208 |
| PY2019 | Recipient | $1,476.97 | 11 |
| PY2019 | Principal investigator | $699,383.42 | 730 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
168 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | CSL Behring | $38,437.00 | 12/29/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667717 |
| Principal investigator 1 | CSL Behring | $1,074.22 | 12/18/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667915 |
| Principal investigator 1 | CSL Behring | $540.54 | 12/18/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 12/17/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 12/17/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 12/15/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 12/15/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 12/15/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 12/15/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,952.00 | 12/15/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718491 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 11/26/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220997094 |
| Principal investigator 1 | CSL Behring | $86.48 | 11/20/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,234.00 | 11/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $338.00 | 11/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,235.00 | 11/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,293.00 | 11/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,844.00 | 11/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718487 |
| Principal investigator 1 | CSL Behring | $19,174.00 | 11/17/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667709 |
| Principal investigator 1 | CSL Behring | $97.31 | 11/17/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667919 |
| Principal investigator 1 | CSL Behring | $291.88 | 11/13/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667897 |
| Principal investigator 1 | CSL Behring | $1,081.08 | 11/12/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667895 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 11/11/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220997092 |
| Principal investigator 1 | Eli Lilly and Company | $77.33 | 11/10/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187889242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718477 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,930.00 | 10/31/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185538142 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,443.79 | 10/30/2025 | Non-covered Recipient Entity CALIFORNIA KIDNEY SPECIALISTS | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190303387 |
| Principal investigator 1 | CSL Behring | $54,590.30 | 10/29/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667701 |
| Principal investigator 1 | CSL Behring | $702.65 | 10/28/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 10/27/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,293.00 | 10/20/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718473 |
| Principal investigator 1 | CSL Behring | $835.38 | 10/07/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,235.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,726.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,844.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,952.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,925.00 | 10/02/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718471 |
| Principal investigator 1 | CSL Behring | $352.45 | 10/02/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667879 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,306.00 | 10/02/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211629868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 09/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220718435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 09/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 09/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.35 | 09/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.64 | 09/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718455 |
| Principal investigator 1 | Novo Nordisk AS | $7,500.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213713874 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213718277 |
| Principal investigator 1 | Novo Nordisk AS | $380.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213734148 |
| Principal investigator 1 | Novo Nordisk AS | $2,100.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213754646 |
| Principal investigator 1 | Novo Nordisk AS | $6,083.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213814483 |
| Principal investigator 1 | Novo Nordisk AS | $846.93 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213818116 |
| Principal investigator 1 | Novo Nordisk AS | $1,295.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213833461 |
| Principal investigator 1 | Novo Nordisk AS | $62.50 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213841213 |
| Principal investigator 1 | Novo Nordisk AS | $475.00 | 09/19/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213847656 |
| Principal investigator 1 | CSL Behring | $32,983.60 | 09/17/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667691 |
| Principal investigator 1 | CSL Behring | $581.61 | 09/08/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718439 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $7,295.68 | 08/27/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185538138 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,665.37 | 08/22/2025 | Non-covered Recipient Entity North America Research Institute | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225413454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,665.00 | 08/20/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718445 |
| Principal investigator 1 | CSL Behring | $41,388.30 | 08/20/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667683 |
| Principal investigator 1 | CSL Behring | $983.29 | 08/18/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667861 |
| Principal investigator 1 | CSL Behring | $16.71 | 08/06/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667873 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 08/05/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220997090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,422.00 | 08/05/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,430.00 | 08/05/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220718433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $279.00 | 07/28/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167305 |
| Principal investigator 1 | CSL Behring | $734.68 | 07/23/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667855 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $1,848.00 | 07/16/2025 | Non-covered Recipient Entity North America Research Institute, Inc. | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931270 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $4,200.00 | 07/16/2025 | Non-covered Recipient Entity North America Research Institute, Inc. | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931272 |
| Principal investigator 1 | CSL Behring | $30,531.90 | 07/16/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667675 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $6,436.00 | 07/08/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211629863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.88 | 07/01/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718443 |
| Principal investigator 1 | CSL Behring | $10,455.00 | 06/30/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667667 |
| Principal investigator 1 | Novo Nordisk AS | $8,840.93 | 06/25/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213721780 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 06/25/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | NN9535-4662 | No dispute reported | 06/30/2026 | 1213816662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220718415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.82 | 06/24/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $246.00 | 06/20/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718555 |
| Principal investigator 1 | CSL Behring | $484.30 | 06/20/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667845 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,650.00 | 06/13/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511653 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,538.00 | 06/13/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511656 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,926.00 | 06/13/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511660 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,080.00 | 06/13/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511664 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,200.00 | 06/13/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511669 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 06/13/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220997088 |
| Principal investigator 1 | CSL Behring | $432.43 | 06/10/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,188.00 | 06/06/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,415.00 | 06/06/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $366.00 | 06/06/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718553 |
| Principal investigator 1 | CSL Behring | $1,178.39 | 06/06/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220718427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 05/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220718429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220718431 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,130.00 | 05/27/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211629859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,489.00 | 05/20/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167350 |
| Principal investigator 1 | CSL Behring | $20,733.00 | 05/14/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667659 |
| Principal investigator 1 | CSL Behring | $1,459.42 | 05/12/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667777 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 05/09/2025 | Non-covered Recipient Entity California Kidney Specialists | Ph III HFrEF study | No dispute reported | 06/30/2026 | 1220997084 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $700.00 | 05/07/2025 | Non-covered Recipient Entity North America Research Institute, Inc. | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930767 |
| Principal investigator 1 | CSL Behring | $1,708.53 | 05/06/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667771 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,494.79 | 05/05/2025 | Non-covered Recipient Entity North America Research Institute | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225412708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,408.00 | 04/25/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.20 | 04/25/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.55 | 04/23/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718557 |
| Principal investigator 1 | CSL Behring | $291.92 | 04/17/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $884.00 | 04/17/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167342 |
| Principal investigator 1 | CSL Behring | $11,148.00 | 04/16/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667651 |
| Principal investigator 1 | CSL Behring | $423.76 | 04/16/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667763 |
| Principal investigator 1 | CSL Behring | $627.04 | 04/11/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667761 |
| Principal investigator 1 | CSL Behring | $16.71 | 04/09/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718535 |
| Principal investigator 1 | CSL Behring | $302.69 | 03/31/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667751 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,200.00 | 03/26/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185538140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 03/25/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 03/25/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.76 | 03/25/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718527 |
| Principal investigator 1 | Janssen Research & Development, LLC | $558.00 | 03/25/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167327 |
| Principal investigator 1 | CSL Behring | $7,086.30 | 03/19/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667643 |
| Principal investigator 1 | CSL Behring | $786.05 | 03/10/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667743 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,664.90 | 03/06/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY | No dispute reported | 06/30/2026 | 1225335609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718515 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,836.70 | 02/21/2025 | Non-covered Recipient Entity NORTH AMERICAN RESEARCH INST | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215511590 |
| Principal investigator 1 | CSL Behring | $483.71 | 02/21/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667727 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 02/19/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220997086 |
| Principal investigator 1 | CSL Behring | $8,195.00 | 02/19/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 01/31/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718517 |
| Principal investigator 1 | Eli Lilly and Company | $59,158.00 | 01/28/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187889238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 01/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.76 | 01/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 01/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 01/27/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718531 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $68,752.14 | 01/24/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185538136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $246.00 | 01/22/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718503 |
| Recipient | Eli Lilly and Company | $24.90 | 01/22/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187873813 |
| Principal investigator 1 | Janssen Research & Development, LLC | $279.00 | 01/21/2025 | Non-covered Recipient Entity N Amercn Rsrch Inst | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167313 |
| Principal investigator 1 | CSL Behring | $1,362.12 | 01/16/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667719 |
| Principal investigator 1 | CSL Behring | $9,614.90 | 01/10/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667629 |
| Principal investigator 1 | CSL Behring | $21,423.20 | 01/10/2025 | Non-covered Recipient Entity North America Research Institute | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667631 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,998.18 | 01/08/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal | No dispute reported | 06/30/2026 | 1185538144 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $798,905.65 | 01/07/2025 | Non-covered Recipient Entity NORTH AMERICA RESEARCH INSTITUTE | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | No dispute reported | 06/30/2026 | 1190302101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity California Kidney Specialists | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220718507 |